-
Achillion Pharma Initiated At Sell By Chardan, Sees ≥60% Downside
Thursday, July 14, 2016 - 11:52am | 340Read More...Chardan Capital’s Madhu Kumar believes Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is faced with several challenges, including lack of clinical data and presence of “competitive barriers” for targeted indications. Kumar initiated coverage of the company with a Sell rating...
-
Chardan Analysts Initiate Coverage On Akari Therapeutics With A Sell Rating
Monday, July 11, 2016 - 9:00am | 313Read More...Although there are catalysts for Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) in 2H16, the inferior dosing schedule for coversin and stiff competition pose risks, Chardan Capital Markets’ Madhu Kumar said in a report. He initiated coverage of the company with a Sell rating and a price target...
-
Chardan Initiates NICE-Systems With Buy Rating, $70 Target
Wednesday, June 22, 2016 - 10:33am | 260Read More...Given its robust cash generation and diversified solutions and clients portfolio, Chardan Capital’s Lena Rogovin believes Nice-Systems Ltd (ADR) (NASDAQ: NICE) is well positioned to further increase its market share, both through M&A and organically. Rogovin initiated coverage of the...
-
ProQR Therapeutics Has Limited Downside Or Upside According to Chardan
Monday, June 20, 2016 - 8:39am | 222Read More...Shares of ProQR Therapeutics NV (NASDAQ: PRQR) have lost 48.2 percent year-to-date. Chardan Capital Markets’ Madhu Kumar initiated coverage of the company with a Neutral rating and a price target of $4.50. The analyst commented that following the underperformance, ProQR’s shares have...
-
Out Of This World? Chardan Grounds Globalstar To Neutral On FCC Decision
Monday, June 13, 2016 - 9:17am | 321Read More...“Lobbying for and against the FCC’s NPRM on TLPS continues with ex partes filed recently suggesting the major focus is on the vote of Commissioner Michael O’Rielly,” Chardan Capital’s James McIlree mentioned. McIlree downgraded the rating on Globalstar, Inc. (NYSE:...
-
Regulus RG-101 Results 'Potentially Breakthrough,' Chardan Says; Target Raised To $20
Tuesday, June 7, 2016 - 11:38am | 318Read More...Chardan Capital Markets analysts Madhu Kumar and Gbola Amusa kept a Buy rating on Regulus Therapeutics Inc (NASDAQ: RGLS) following the positive top-line data on Hepatitis C virus treatment. The brokerage boosted its price target to $20 from $15.00 on the shares. The analysts said their...
-
Chardan Expecting Nearly 50% Downside In Sage Therapeutics, Starts At Sell
Tuesday, May 24, 2016 - 7:03am | 273Read More...SAGE Therapeutics Inc (NASDAQ: SAGE) is expected to announce Phase 3 data for its lead candidate SAGE-547 [allopregnanolone] in super-refractory status epilepticus [SRSE] in 2H16. Chardan Capital Markets' Gbola Amusa initiated coverage of the company with a Sell rating and a price target of $...
-
Chardan Initiates Asterias Biotherapeutics At Buy On Potential Cell Therapy Competitiveness
Monday, May 23, 2016 - 11:46am | 478Read More...Chardan Capital Markets has started coverage of Asterias Biotherapeutics Inc (NYSE: AST) with a Buy rating and $5.50 price target, saying the company "has the potential to become a significant competitor in the emerging fields of cell therapy and regenerative medicine." "Asterias is developing...
-
Analyst Highlights Regulus Therapeutics' 'Disruptive 2016 Catalysts'
Wednesday, April 13, 2016 - 8:14am | 328Read More...Chardan Capital’s Madhu Kumar expects Regulus Therapeutics Inc (NASDAQ: RGLS)'s assets to witness several “value-enhancing” catalysts over the coming months. The analyst initiated coverage of Regulus Therapeutics with a Buy rating and price target of $15. ‘Disruptive...
-
CaesarStone Initiated With Buy Rating, $44 Price Target At Chardan
Wednesday, April 6, 2016 - 7:53am | 261Read More...Shares of Caesarstone Sdot-Yam Ltd (NASDAQ: CSTE) have been under pressure on concerns over a slowdown in US revenue growth. Chardan Capital Markets’ Lena Rogovin initiated coverage of the company with a Buy rating and a price target of $44. The US represents CaesarStone’s largest...
-
'No Mas': Chardan Downgrades DigitalGlobe
Friday, February 26, 2016 - 8:42am | 258Read More...Chardan Capital's James McIlree downgraded the rating on DigitalGlobe Inc (NYSE: DGI) to Neutral. "For many quarters the company has struggled to grow revenues in US Value added services, which declined from $118 million in 2014 to $95.4 million in 2015. We think it will fall again in...
-
Chardan Starts Coverage Of Mesoblast, Sees 'Large Market Opportunities'
Friday, February 19, 2016 - 10:21am | 257Read More...Chardan Capital’s Keay Nakae has initiated coverage of Mesoblast limited (ADR) (NASDAQ: MESO) with a Neutral rating and price target of $5.50. Nakae believes that there are several positives for the company, such as its proprietary mesenchymal lineage adult stem cells (MLCs), which can be...
-
Chardan: Sell Regeneron After Sanofi Drops Patent Infringement Bombshell
Wednesday, February 10, 2016 - 10:30am | 308Read More...Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares have been trending south this year, and are down 33 percent since January 4. Chardan Capital Markets’ Gbola Amusa maintained a Sell rating for the company, with a price target of $400. Acceptance by Regeneron Pharmaceuticals...
-
A Market-Leading Robotics IoT Play: iRobot
Wednesday, February 10, 2016 - 9:42am | 344Read More...Shares of iRobot Corporation (NASDAQ: IRBT) have appreciated 14.15 percent over the past six months, rising almost to their 52-week high on December 17 of $36.95 Chardan Capital’s Marc Estigarribia has initiated coverage of the company with a Buy rating and price target of $42....
-
Here's Chardan's 'Conviction Sell' On Axovant
Wednesday, February 3, 2016 - 1:58pm | 479Read More...According to a note out Wednesday, Chardan Capital Markets has a conviction sell rating on Axovant Sciences Ltd (NYSE: AXON). Citing concerns of overpricing RVT-101 following Axovant's IPO, mixed biopharma data in-lab and consensus estimates as "implausibly high," the firm has a...
